| [1] |
WU Chunxiao, PANG Yi, GU Kai, YAN Jiaying, WANG Chunfang, XIANG Yongmei, SHI Yan.
Survival analysis of female breast cancer in Shanghai: a population-based study from 2002 to 2017
[J]. China Oncology, 2025, 35(3): 291-297.
|
| [2] |
SHEN Jie, LIU Wanlin, WANG Zezhou, MU Sibo, MO Miao, ZHOU Changming, YUAN Jing, WANG Yu, ZHENG Ying, JI Qinghai.
Survival and cause-of-death analysis of 55 thousand thyroid cancer cases in China from a large single institution hospital-based cancer registry database
[J]. China Oncology, 2025, 35(1): 68-76.
|
| [3] |
LIU Shuai, ZHANG Kai, ZHANG Xiaoqing, LUAN Wei.
An exploratory study on the perioperative treatment of locally advanced gastric cancer with combination of penpulimab, anlotinib and chemotherapy
[J]. China Oncology, 2024, 34(7): 659-668.
|
| [4] |
SHEN Jie, FENG Xiaoshuang, WEN Hao, ZHOU Changming, MO Miao, WANG Zezhou, YUAN Jing, WU Xiaohua, ZHENG Ying.
Metastasis patterns and survival analysis of 572 patients with metastatic cervical cancer: a hospital-based real world study
[J]. China Oncology, 2024, 34(4): 361-367.
|
| [5] |
SHEN Jie, WANG Jiangli, WANG Zezhou, MO Miao, ZHOU Changming, YUAN Jing, XU Dazhi, ZHENG Ying.
Survival analysis of 6 737 surgically resected gastric cancer cases in China from a large single institution hospital-based cancer registry database
[J]. China Oncology, 2024, 34(3): 268-277.
|
| [6] |
LI Jing, ZHENG Lei, GAO Yu.
Analysis of effects of trastuzumab assisted modified DOF fortnightly regimen on serum tumor markers and survival rate in patients with cisplatin-resistant gastric cancer
[J]. China Oncology, 2024, 34(3): 286-292.
|
| [7] |
CHEN Luyan, WANG Lixue, FU Peifen.
The value of surgery in the patients with de novo stage Ⅳ breast cancer
[J]. China Oncology, 2023, 33(5): 431-436.
|
| [8] |
LIU Yiming, FAN Lei, MO Miao, SHAO Zhimin, YU Keda.
Factors-associated with short-term effect and long-term survival of ovarian function suppression in estrogen receptor positive breast cancer: a retrospective analysis
[J]. China Oncology, 2022, 32(8): 705-711.
|
| [9] |
HONG Yaping, HUANG Yunjian, HUANG Zhangzhou, CHEN Shengjia, ZHONG Qiaofeng, ZENG Hongfu, ZHUANG Wu.
Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer
[J]. China Oncology, 2022, 32(7): 624-634.
|
| [10] |
ZHOU Changshuai, YANG Yuechao, CUI Huanhuan, CHEN Lei, CHEN Xin, HAO Bin, TONG Tong, CAO Yiqun.
Prognostic factor analysis of surgical treatment for cerebellar metastases in 36 patients
[J]. China Oncology, 2022, 32(4): 357-362.
|
| [11] |
WANG Zimao, CAO Yuan, WANG Qiying.
Construction and validation of the survival prediction model for patients with cutaneous spindle cell melanoma
[J]. China Oncology, 2022, 32(3): 234-242.
|
| [12] |
LI Ting, XU Yu, JIA Dongdong, LIAO Zhichao, SUN Wei, WU Haixiao, REN Zhiwu, ZHAO Jun, XING Ruwei, TENG Sheng, YANG Yun, CHEN Yong, LI Tao, YANG Jilong.
Adjuvant therapy with anti-PD-1 antibody vs targeted therapy for patients with resected stage Ⅲ malignant melanoma: a real-world data analysis from China centers
[J]. China Oncology, 2022, 32(12): 1147-1157.
|
| [13] |
LIN Yi, WANG Ce, KANG Xun, KANG Zhuang, CHEN Feng, JIANG Bo, LI Wenbin.
Screening recurrent glioblastoma-related genes and analyzing their gene expressions in association with clinicopathological parameters and prognosis
[J]. China Oncology, 2022, 32(1): 13-23.
|
| [14] |
WANG Zezhou , ZHANG Yang , MO Miao , YUAN Jing , ZHOU Changming , SHEN Jie , FENG Xiaoshuang , WU Haoxuan , LI Hang , YE Ting , HU Hong , CHEN Haiquan , ZHENG Ying .
Distribution of metastatic sites and survival analysis of patients with non-metastatic lung cancer at initial diagnosis based on hospital registration
[J]. China Oncology, 2021, 31(9): 775-782.
|
| [15] |
CAI Shumo, TANG Jie, HUANG Xiao, HUANG Xiaowei, LIU Suping, KE Guihao, ZHENG Zhong, CHENG Xi, TANG Meiqin.
Three-step chemotherapy treatment for platinum-sensitive recurrent ovarian cancer: a review of 20 cases
[J]. China Oncology, 2021, 31(4): 330-334.
|